White Paper

Digitization Of The Supply Chain: Challenges In Scaling Up Cell & Gene Therapy

Field Service Reverse Logistics

Personalized medicine has become a reality for many conditions, for example read about one of the first C&G therapy patients, Novartis patient #1: Emily Whitehead. The list of C&G therapies is expanding fast as more trials are succeeded by more FDA approvals.

Even in patients with the same disease, generic medicines will commonly help some patients, while having minimal effects on few and potentially adverse effects on others. In contrast, new personalized treatments such as C&G therapy, based on our improved understanding of genetics, the immune system and stem cells, are specifically designed and manufactured for individual patients. This is a unique difference to traditional pharmaceutical manufacturing because C&G therapy is made to order rather than made to stock. Additionally, for each patient, the manufacturing process starts with patient-specific material and requires sensitive inbound and outbound logistics.

VIEW THE WHITE PAPER!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Cell & Gene? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
I'm interested in newsletter subscriptions.
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to:

Werum IT Solutions America, Inc.